glp-1 lupus glp 1 lupus At Lupus LA's #LatestOnLupus Conference at UCLA, Dr. Daniel Wallace shared emerging insights into the use of GLP-1 receptor agonists A Closer Look at the

Overall, our results clearly show that KA and HQ have different inhibition modes on TyrBm monophenolase (L-tyrosine) and diphenolase (L-dopa) activities

CB-839, an inhibitor targeting GLS, has shown good tumor inhibition activity, tolerance, and safety in preclinical studies and phase I clinical trials in solid tumors

Acting like a traffic director at an injury site, BPC-157 can signal blood vessels to expand, cells to move into damaged areas, and inflammation to subside

The identification of multiple single-nucleotide polymorphisms (SNPs) associated with NAFLD has significantly advanced our understanding of the diseases genetic architecture